CN113248572B - Anti-multidrug-resistant bacteria cyclopeptide and application thereof - Google Patents
Anti-multidrug-resistant bacteria cyclopeptide and application thereof Download PDFInfo
- Publication number
- CN113248572B CN113248572B CN202110477846.4A CN202110477846A CN113248572B CN 113248572 B CN113248572 B CN 113248572B CN 202110477846 A CN202110477846 A CN 202110477846A CN 113248572 B CN113248572 B CN 113248572B
- Authority
- CN
- China
- Prior art keywords
- arg
- trp
- cpeptide
- antibacterial
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010069514 Cyclic Peptides Proteins 0.000 title claims abstract description 63
- 102000001189 Cyclic Peptides Human genes 0.000 title claims abstract description 63
- 241000894006 Bacteria Species 0.000 title claims description 19
- 239000003814 drug Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 241000588626 Acinetobacter baumannii Species 0.000 claims abstract description 7
- 241000588724 Escherichia coli Species 0.000 claims abstract description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 5
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 53
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 45
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 18
- 125000002091 cationic group Chemical group 0.000 abstract description 17
- 230000001580 bacterial effect Effects 0.000 abstract description 11
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 abstract description 7
- 239000007790 solid phase Substances 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 2
- 150000001768 cations Chemical class 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 239000011347 resin Substances 0.000 description 17
- 229920005989 resin Polymers 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000000845 anti-microbial effect Effects 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 230000002949 hemolytic effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 10
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 229960002182 imipenem Drugs 0.000 description 6
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 6
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- TZCYLJGNWDVJRA-UHFFFAOYSA-N 6-chloro-1-hydroxybenzotriazole Chemical compound C1=C(Cl)C=C2N(O)N=NC2=C1 TZCYLJGNWDVJRA-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VXGGBPQPMISJCA-STQMWFEESA-N (2s)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoyl]amino]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 VXGGBPQPMISJCA-STQMWFEESA-N 0.000 description 1
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an anti-multidrug-resistant bacterial cyclopeptide and application thereof, which is characterized in that an amino acid sequence is any one of the following six types: R-R-W-W-W-R, R-W-R-W-R-W, R-R-W-W-R-R, R-R-W-R-R-W, R-R-W-W-W-R-R, R-R-W-W-R-R-R-W. The antibacterial cyclopeptide is obtained by cyclization of any one of the amino acid sequences. The invention provides 6 novel antibacterial peptides of artificially designed cations. The antibacterial peptides can be synthesized by Fmoc solid phase chemistry. The cationic antibacterial peptide has broad-spectrum killing activity on multiple drug-resistant acinetobacter baumannii, staphylococcus aureus and escherichia coli, has no toxic action on animal and plant cells, and has strong operability and low cost.
Description
Technical Field
The invention relates to a cyclic peptide for resisting multiple drug-resistant bacteria and application thereof, and relates to the field of cyclic peptide.
Background
With the wide clinical application of antibiotics, multidrug-resistant bacteria are also continuously appearing and increasing. In recent years, the emergence of multi-drug resistant gram-negative bacteria (escherichia coli, pseudomonas aeruginosa, acinetobacter baumannii) and gram-positive bacteria (staphylococcus aureus), which are the most common cause of nosocomial infections, has been an increasing problem and challenge worldwide. In the face of increasingly serious drug resistance problems, however, enough drugs for solving the problems have not been developed yet, polymyxins (such as colistin) become the last effective means for treating drug-resistant bacterial infections again, and therefore, the development of novel antibacterial drugs is urgently needed.
The antibacterial peptide (AMP) is a short peptide existing in all organisms, has the characteristics of cationic property and amphipathy, has various structures, is an important component of a natural immune system of the organisms to resist the invasion of pathogenic bacteria, and keeps stable and efficient in the biological evolution process. The antibacterial peptide has good water solubility and high thermal stability, has biological effects of broad-spectrum antibiosis, antifungal, antivirus, antitumor cell and the like, and can also be used as an immunomodulator to play a plurality of immune effects in organisms, such as acting as a chemotactic factor, inducing the generation of the chemotactic factor, promoting wound healing, regulating dendritic cell and cellular immune response and the like. Most of antibacterial peptides kill bacteria through a unique cell membrane damage mechanism, the action mode is different from that of the currently clinically used antibiotics, pathogenic bacteria hardly generate drug resistance of the antibacterial peptides through changing cell membrane components, and therefore the antibacterial peptides show good application prospects in the aspect of treating infection caused by drug-resistant bacteria, are widely concerned in recent years, and become a hotspot for research and development of novel antibacterial drugs.
In order to find antimicrobial peptides from polypeptides, one initially studied polypeptides by conducting experiments and identified them by observing whether they have antimicrobial activity. In this way, although it can be accurately determined whether the polypeptide has an antimicrobial effect. However, the experimental procedure is cumbersome, takes a long time, requires a large amount of money, and cannot predict the activity of the antimicrobial peptide. With the development of high-throughput proteomics, the number of protein and polypeptide sequences has increased rapidly. It is difficult to identify effective antimicrobial peptides from a large number of peptide samples and to experimentally predict their antimicrobial activity. Therefore, there is a need to find additional methods to identify and predict effective antimicrobial peptides. With the continuous development of bioinformatics, computational methods are used for screening and activity prediction, which effectively solve various disadvantages of experimental methods.
Disclosure of Invention
Aiming at the technical problems, the invention aims to provide the anti-multiple drug-resistant cyclopeptide and also provides the application of the anti-multiple drug-resistant cyclopeptide, wherein the anti-multiple drug-resistant cyclopeptide has the advantages of strong antibacterial activity, low cost and low hemolytic toxicity.
In order to achieve the purpose, the technical scheme of the invention is as follows: the cyclic peptide for resisting multiple drug resistance bacteria is characterized in that the amino acid sequence is any one of the following six types:
CPeptide-A:R-R-W-W-W-R(Arg-Arg-Trp-Trp-Trp-Arg)
CPeptide-B:R-W-R-W-R-W(Arg-Trp-Arg-Trp-Arg-Trp)
CPeptide-C:R-R-W-W-W-R-R(Arg-Arg-Trp-Trp-Trp-Arg-Trp)
CPeptide-D:R-R-W-W-R-R-W(Arg-Arg-Trp-Trp-Arg-Arg-Trp)
CPeptide-E:R-R-W-W-W-W-R-R(Arg-Arg-Trp-Trp-Trp-Trp-Arg-Arg)
CPeptide-F:R-R-W-W-R-R-R-W(Arg-Arg-Trp-Trp-Arg-Arg-Arg-Trp)。
the structural formulas after cyclization are respectively as follows:
CPeptide-A:
CPeptide-B:
CPeptide-C:
CPeptide-D:
CPeptide-E:
CPeptide-F:
the invention designs cationic cyclic peptide based on sequence and structure analysis of natural antibacterial peptide. Is prepared from bovine lactoferrin LfcinB6 4-9 (RRWQWR) is used as a template, polypeptide sequence characteristics are combined, an optimal amino acid combination sequence is obtained through virtual combination design and screening, and a restricted conformation can be better formed based on cyclic peptide, so that the binding capacity with a target molecule and the selectivity on a corresponding receptor are enhanced, and the polypeptide has the characteristics of easiness in penetrating a bacterial pellicle, low toxicity, resistance to endopeptidase and exopeptidase hydrolysis and the like. On the basis, amino acid sequence design and transformation are carried out and cyclized to construct an antibacterial cyclic peptide library. And (3) taking the BamA protein as a target, and virtually screening by molecular docking to obtain the potential antibacterial cyclic peptide. The 6 linear peptides which are designed and screened are respectively 'RRWWWR', 'RWRWRRW', 'RRWWWRR', 'RRWWRRW', 'RRWWWWWR', 'RRWWRRRW', and experimental researches show that the peptides have strong antibacterial ability and small hemolytic toxicity after cyclization.
The preparation method of the novel cationic antibacterial cyclic peptide is a solid-phase synthesis method of polypeptide, firstly resin is required to be swelled, then C-terminal carboxyl of a first amino acid is reacted with active site chlorine on the resin, after the first amino acid is connected on the resin, dehydration condensation is carried out to connect a second amino acid, and Fmoc protection is removed after condensation is completed. Repeating the operation according to the designed amino acid sequence, sequentially completing the rest amino acids, and finally cutting the fully-protected linear polypeptide from the resin by using a cutting reagent. Reacting the fully protected linear peptide with a condensing agent DIC/Cl-HOBt, adding water to precipitate a solid after the reaction to obtain the protected cyclic peptide, 95% of 2 And cracking O at room temperature for 2 hours to obtain a cyclic peptide primary product.
In order to deeply research the relationship between the structure and the function of the bioactive antibacterial peptide, the sterilization and bacteriostasis capacities of the polypeptide are detected by an agar perforation method and a minimum bacteriostasis concentration experiment, and the clinical common antibiotic imipenem is used as a positive control, and the result shows that the sterilization activity and the bacteriostasis capacity of the antibacterial cyclic peptide are equivalent to those of imipenem.
The detection of the cytotoxicity of the antibacterial cyclic peptide in normal cells is a necessary measure which can be clinically used, and the antibacterial effect of the cationic antibacterial cyclic peptide is that the cationic antibacterial cyclic peptide has electropositivity and can generate electrostatic attraction with negatively charged phosphatidyl glycerol and cardiolipin in a cell membrane, so that the structure of the cell membrane of bacteria is damaged and the bacteria is prevented from being bacteria. However, since phosphatidylserine and phosphatidylinositol, etc. are present in the cell membrane of eukaryotic cells, they are negatively charged, and may cause the binding of the antibacterial cyclic peptide to the cell membrane of eukaryotic cells, resulting in cytotoxicity. Therefore, the hemolytic toxicity of the polypeptide needs to be detected, and experiments show that the hemolytic rate of the antibacterial peptide is still very low at high concentration, which proves that the hemolytic toxicity of the antibacterial cyclic peptide is very low.
The second object of the present invention is achieved by: an application of the multi-drug resistant cyclopeptide in antibiosis.
An application of the multidrug-resistant cyclopeptide in multidrug-resistant acinetobacter baumannii, escherichia coli and staphylococcus aureus resistance.
Has the beneficial effects that: the invention provides 6 novel antibacterial cyclic peptides of artificially designed cations. The antibacterial cyclic peptide can be synthesized by adopting Fmoc solid phase chemical method. The cationic antibacterial cyclic peptide has broad-spectrum killing activity on multiple drug-resistant acinetobacter baumannii, staphylococcus aureus and escherichia coli, has no toxic action on animal and plant cells, and is high in operability and low in cost.
Drawings
FIG. 1 is a mass spectrum of the antimicrobial cyclic peptide CPeptide-A.
FIG. 2 is a mass spectrum of the antimicrobial cyclic peptide CPeptide-B.
FIG. 3 is a mass spectrum of the antimicrobial cyclic peptide CPeptide-C.
FIG. 4 is a mass spectrum of the antimicrobial cyclic peptide CPeptide-D.
FIG. 5 is a mass spectrum of the antimicrobial cyclic peptide CPeptide-E.
FIG. 6 is a mass spectrum of the antimicrobial cyclic peptide CPeptide-F.
Detailed Description
The invention is further illustrated by the following examples in conjunction with the accompanying drawings:
artificially synthesizing target products CPeptide-A, CPeptide-B, CPeptide-C, CPeptide-D, CPeptide-E and CPeptide-F according to a standard Fmoc solid phase program:
CPeptide-A:(Arg-Arg-Trp-Trp-Trp-Arg),
CPeptide-B:(Arg-Trp-Arg-Trp-Arg-Trg),
CPeptide-C:(Arg-Arg-Trp-Trp-Trp-Arg-Arg),
CPeptide-D:(Arg-Arg-Trp-Trp-Arg-Arg-Trp),
CPeptide-E:(Arg-Arg-Trp-Trp-Trp-Trp-Arg-Arg),
CPeptide-F:(Arg-Arg-Trp-Trp-Arg-Arg-Arg-Trp),
the synthesized product was purified by reverse phase liquid chromatography (Vydac 218TP1022 column 2.2 x 25cm), eluted with acetonitrile/water system and then analyzed by mass spectrometry. The sequence of the prepared CPeptide-A polypeptide is as follows: R-R-W-W-W-W-R (Arg-Arg-Trp-Trp-Trp-Arg), the CPeptide-B polypeptide sequence is R-W-R-W-R-W (Arg-Trp-Arg-Trp-Arg-Trg), the CPeptide-C polypeptide sequence is R-R-W-W-W-R-R (Arg-Arg-Trp-Trp-Trp-Arg-Arg), the CPeptide-D polypeptide sequence is R-R-W-W-R-W (Arg-Arg-Trp-Trp-Arg-Arg-Arg), the CPeptide-E polypeptide sequence is R-R-W-W-W-R-R (Arg-Arg-Trp-Trp-Trp-Arg-Arg), and the CPeptide-F polypeptide sequence is R-R-W-W-W-R-R-Arg-Trp-Trp-Arg-Arg-Arg-P-Arg-Arg-F.
Example 1
1. CPeptide-A (Arg-Arg-Trp-Trp-Trp-Arg), cyclic peptide synthesis.
Fmoc solid-phase polypeptide synthesis is adopted, 2-CTC resin is used as a carrier, full-protection peptide linear peptide is synthesized firstly, cyclization is carried out in a liquid phase, and finally, deprotection is carried out by TFA liquid, and ether precipitation is carried out to obtain crude peptide.
1g of the initial resin was swollen with 10ml of DCM for 30min at room temperature;
first amino acid coupling procedure:
weighing protected amino acid Fmoc-Arg (Pbf) -OH with the total resin substitution value of 3eq, adding the protected amino acid Fmoc-Arg-OH into a DCM solution, adding DIEA with the total resin substitution value of 9eq for dissolution, adding the dissolved clear solution into resin for coupling reaction for 3h, discharging waste liquid, and washing with DMF for 3 times.
Second amino acid coupling procedure:
removing Fmoc protecting groups: adding 5ml of 20% PPD/DMF reagent into the reaction tube for reaction for 5min, discharging the reaction liquid, and adding 5ml of 20% PPD/DMF solution again for reaction for 25min;
washing after deprotection: washing with DMF solution for 8 times, each for 3min, and each amount is 5ml; after washing, taking a small amount of resin, and carrying out color development detection on the resin by using a bromophenol blue solution, wherein the resin is in a deep color;
coupling Fmoc-AA-OH: weighing 3eq of amino acid to be coupled and protected and 3eq of Cl-HOBt, adding 4ml of DMF for dissolving, adding 3eq of DIC after dissolving, oscillating and mixing for 1-2min, adding the solution into a reaction tube, and reacting with the deprotected resin at room temperature for 1.5h;
washing after coupling: the resin was washed 5 times with DMF, 3min each time, 5ml each time. After washing, taking a small amount of resin, and carrying out color development detection by using bromophenol blue solution, wherein the resin is almost colorless.
Coupling all the protected amino acids in turn according to a second amino acid coupling mode, removing the Fmoc protecting group of the last protected amino acid, washing with DMF for 4 times, then washing with DCM for 5 times, and vacuum-drying under reduced pressure.
The resin was cleaved 3-5 times with 5 volumes by weight of TFA/DCM (concentration 2% or so) for 3 minutes each time. The lysate was immediately taken as 10% NaHCO 3 The solution was adjusted to neutral. And combining the lysates for multiple times, concentrating under vacuum and reduced pressure, separating out a solid, filtering and washing with water. And drying the solid under vacuum and reduced pressure to obtain the fully-protected linear peptide.
The fully protected linear peptide was dissolved in THF or DCM, and if the solubility was poor, a little DMF was added to aid the dissolution. The final concentration of the fully protected linear peptide is controlled to be below 5 mg/ml. Adding a condensing agent DIC/Cl-HOBt for reaction, and monitoring the reaction process by a liquid phase.
After the reaction, the solvent was distilled off, and water was added to precipitate a solid. And washing the solid with water and drying to obtain the fully-protected cyclic peptide.
The total protected cyclic peptide was 95% TFA/H 2 And (3) cracking the O at room temperature for 2h, adding methyl tert-butyl ether to separate out a crude product, washing, drying and inspecting.
The crude peptide was purified using a preparative liquid phase.
Firstly, dissolving crude peptide with 30-50mL of 50% acetonitrile solution, carrying out ultrasonic treatment for 2min, filtering the dissolved solution with a filter membrane, taking 3uL of solution, and analyzing the crude peptide by using analytical grade HPLC. Gradient elution is carried out by using water and acetonitrile as mobile phases for 30min, HPLC is firstly balanced for 5min, and then sample injection is carried out. And dissolving the sample, injecting the sample, collecting the sample, and preparing the dissolved sample for injection. Preparative HPLC equilibrated for 10min with an initial gradient: water 95%, acetonitrile 5%, end gradient: 25% of water, 75% of acetonitrile and 40min of gradient time. The sample from the detector is collected.
The preparation of other antibacterial cyclopeptides is the same as that of CPeptide-A (Arg-Arg-Trp-Trp-Trp-Arg), and the structural formulas of the finally prepared antibacterial cyclopeptides are respectively as follows:
CPeptide-A:
CPeptide-B:
CPeptide-C:
CPeptide-D:
CPeptide-E:
CPeptide-F:
identification of antibacterial cyclic peptides
After mass spectrum analysis, the molecular weights of the prepared antibacterial cyclic peptides CPeptide-A, CPeptide-B, CPeptide-C, CPeptide-D, CPeptide-E and CPeptide-F are 1027.20, 1027.35, 1183.20, 1183.40, 1369.80 and 1339.60 respectively, and the theoretical values calculated by polypeptide sequences are 1027.20, 1027.20, 1183.39, 1183.39, 1369.60 and 1339.58. The prepared polypeptide is proved to be the designed CPeptide-A, CPeptide-B, CPeptide-C, CPeptide-D, CPeptide-E, CPeptide-F antibacterial cyclic peptide. And identifying qualified antibacterial cyclic peptide products for later use. The control antimicrobial peptide LfcinB64-9 was prepared using a synthetic method similar to that for the CPeptide-A antimicrobial peptide.
Experimental example 1 measurement of bactericidal Activity of cationic antibacterial Cyclic peptide
The various strains used in the following examples were purchased from the china biologies institute.
The bactericidal activity of the cationic antibacterial cyclic peptide is detected by an agar perforation method, and the bactericidal activity of CPeptide-A, CPeptide-B, CPeptide-C, CPeptide-D, CPeptide-E, CPeptide-F in the invention is evaluated by taking cationic antibacterial peptide LfcinB64-9 RRWQWR synthesized by a solid phase chemical method as a control.
The bactericidal activity of the antimicrobial peptide is determined according to the following steps:
recovering strains: inoculating drug-resistant acinetobacter baumannii into NA nutrient agar culture medium, streaking, and culturing in a constant-temperature incubator at 37 ℃ for 16-20 hours.
And (3) strain culture: selecting single colony, placing in 100ml MHB culture medium for culturing at the same optimum growth temperature of 37 ℃ and the shaking table rotation speed of 160 r/min, and performing shaking culture (16-20 h) to enable the growth state of bacteria to reach logarithmic phase.
Preparing a bacterial suspension: the concentration of bacteria is generally measured by a turbidimetric tube (McLeod) with a turbidity of about 0.5 McLeod, at which the bacterial colony count is about 1.5X 10 8 cfu/ml, then diluted to 10 as 1 5 -10 6 cfu/ml bacterial suspension.
And (3) antibacterial experiments: uniformly coating the diluted bacterial suspensions on 25ml of NA culture medium according to the amount of 0.1ml per plate; and (5) after the bacterial liquid is solidified, punching (the diameter is 9 mm). Adding 50ul (1 mg/ml, 0.5mg/ml, 0.25 mg/ml) of imipenem to the positive control; negative control, adding 50ul deionized water; 50ul (1 mg/ml, 0.5mg/ml, 0.25 mg/ml) of the antimicrobial peptide solution was added to each of the other wells. And (3) performing bacterial culture in a constant-temperature incubator at 37 ℃, and measuring the size of a bacteriostatic zone of the bacteria after 16h, so that the size of the bacteriostatic activity of the bacteria can be preliminarily determined, and three groups of parallel experiments are performed.
TABLE 1 inhibition zone diameter (mm) of cyclic peptides of different concentrations against multiple drug-resistant strains of Acinetobacter baumannii
Note: the diameter of the zone of inhibition is less than or equal to 9mm, and the product is judged to have no inhibition effect
The results show that the cationic antibacterial peptide of the invention has obvious bactericidal capacity and is superior to the reference antibacterial peptide LfcinB6 4-9 (RRWQWR), especially the antibacterial effect of the antibacterial cyclopeptide CPeptide-D is obviously higher than that of other antibacterial cyclopeptides and is close to imipenem.
Experimental example 2 measurement of bacteriostatic Activity of cationic antibacterial Cyclic peptide
The various strains used in the following examples were purchased from the china institute for biologicals assay.
The minimum bacteriostatic ability of the cationic antibacterial cyclic peptide is measured, and the cationic antibacterial peptide LfcinB6 synthesized by a solid phase chemical method is used 4-9 RRWQWR was used as a control to evaluate the bacteriostatic ability of CPEPTIDE-A, CPeptide-B, CPeptide-C, CPeptide-D, CPeptide-E, CPeptide-F of the present invention.
The antibacterial activity of the antibacterial cyclic peptide is determined according to the following steps:
the log phase grown bacteria were collected, centrifuged at 8000 rpm for 2min at 4 ℃, washed 3 times with physiological saline, and fresh broth was added to give a bacterial suspension concentration of 2.0X 105cfu/mL. 50uL of the bacterial suspension (100 uL PBS in the peripheral wells) was added to the experimental wells of the 96-well cell culture plate, and 50uL of peptide solutions (imipenem solution) with different concentrations were added, so that the final concentration (ug/mL) of the peptide solution (imipenem solution) in each well of the horizontal row was: 512. 256, 128, 64, 32, 16, 12, 4. The PBS buffer solution with the same volume is used as a growth control group, three parallel groups are arranged in each group, after a cell culture plate is covered, the cell culture plate is placed in a biochemical incubator at 37 ℃ for culture for 12 hours, and the growth condition (OD 600 nm) of bacteria in each hole is determined through full-automatic enzyme mapping. The Minimum Inhibitory concentration MIC (Minimum Inhibitory Concentrations) is defined as the peptide concentration in the well where bacterial growth is completely inhibited.
Table 2 comparison of the antimicrobial activity Minimum Inhibitory Concentrations (MIC) of the antimicrobial cyclopeptides against different bacteria
The smaller the minimum inhibitory concentration value in the table, the stronger the antibacterial ability of the antibacterial cyclic peptide. As can be seen from the above table, the six antibacterial cyclic peptides of the present invention have lower minimum inhibitory concentrations and MIC ratios of LfcinB6 than the control peptide 4-9 All are much smaller, which shows that the antibacterial ability of the cationic antibacterial cyclic peptide of the invention is far stronger than that of the control antibacterial peptide.
EXAMPLE 3 in vitro assay for hemolytic Activity
This example was used to determine the hemolytic rate of cationic antimicrobial cyclic peptide to sheep red blood cells, and used cationic antimicrobial peptide LfcinB64-9 RRWQWR synthesized by solid phase chemistry as a control. The blood samples used were obtained from defibrinated sheep blood.
The method for detecting the hemolytic rate of the cationic antibacterial cyclic peptide comprises the following steps:
selecting sheep blood cells, centrifuging at 4 ℃ at 3000 r/min for 10min, discarding the supernatant, washing the lower layer red blood cells with normal saline for 3 times, and then resuspending into 3% red blood cell suspension. Add 100uL of peptide solutions at different concentrations to EP tubes, the final concentration of peptide solution in each tube (ug/mL) was: 256. 128, 64, 32, 16, 4, 100uL of red blood cell suspension was added. Each set is provided with three parallel sets. The negative control group was added with an equal volume of physiological saline, and the positive control group was added with 100uL of 0.1% Triton-X100. And (3) culturing the reaction solution in a biochemical incubator at 37 ℃ for 0.5h, taking out, centrifuging at 3000 r/min for 10min, absorbing 100uL of supernatant, transferring to a 96-well plate, and measuring the absorbance at the wavelength of 570nm by using an enzyme-labeling instrument. The experiment was repeated three times and the data averaged.
Hemolysis rate = [ (OD) Test well -OD Negative hole )/(OD Positive hole -OD Negative hole )]×100%
The results are shown in Table 3.
TABLE 3 results of the determination of hemolytic activity of antibacterial cyclic peptide
A lower value of the hemolysis value of the antimicrobial peptide indicates a lower toxicity of the antimicrobial peptide. As can be seen from the table, in comparison with the control
Compared with the peptide, the hemolytic toxicity of the antibacterial cyclic peptide CPeptide-A, CPeptide-B, CPeptide-C, CPeptide-D, CPeptide-F is smaller, while the hemolytic toxicity of the antibacterial cyclic peptide CPeptide-E is larger at high concentrations of 256 and 128, but the antibacterial cyclic peptide CPeptide-E still has certain research value based on good antibacterial activity.
The present invention is not limited to the above-described embodiments, and those skilled in the art will understand that: various changes, modifications, substitutions and alterations can be made to the embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the claims and their equivalents.
Sequence listing
<110> Chongqing university of science and technology
<120> anti-multidrug-resistant cyclopeptide and application thereof
<130>
<160>6
<210> 1
<211>6
<212> PRT
<213> Artificial Synthesis
<220>
<223>CPeptide-A
<400> 1
Arg-Arg-Trp-Trp-Trp-Arg
1 6
<210> 2
<211> 6
<212> PRT
<213> Artificial Synthesis
<220>
<223>CPeptide-B
<400> 2
Arg-Trp-Arg-Trp-Arg-Trp
1 6
<210> 3
<211>7
<212> PRT
<213> Artificial Synthesis
<220>
<223>CPeptide-C
<400> 3
Arg-Arg-Trp-Trp-Trp-Arg-Trp
1 7
210> 4
<211> 7
<212> PRT
<213> Artificial Synthesis
<220>
<223>CPeptide-D
<400> 4
Arg-Arg-Trp-Trp-Arg-Arg-Trp
1 7
<210> 5
<211> 8
<212> PRT
<213> Artificial Synthesis
<220>
<223>CPeptide-E
<400> 5
Arg-Arg-Trp-Trp-Trp-Trp-Arg-Arg
1 8
<210> 6
<211>8
<212> PRT
<213> Artificial Synthesis
<220>
<223>CPeptide-F
<400>6
Arg-Arg-Trp-Trp-Trp-Trp-Arg-Arg
1 8
Claims (1)
1. The application of the multi-drug resistant bacteria cyclopeptide in the preparation of the drugs for resisting the multi-drug resistant acinetobacter baumannii, staphylococcus aureus and escherichia coli is characterized in that the amino acid sequence is as follows:
CPeptide-D:R-R-W-W-R-R-W(Arg-Arg-Trp-Trp-Arg-Arg-Trp)
the structural formulas after cyclization are respectively as follows:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110477846.4A CN113248572B (en) | 2021-04-30 | 2021-04-30 | Anti-multidrug-resistant bacteria cyclopeptide and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110477846.4A CN113248572B (en) | 2021-04-30 | 2021-04-30 | Anti-multidrug-resistant bacteria cyclopeptide and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113248572A CN113248572A (en) | 2021-08-13 |
CN113248572B true CN113248572B (en) | 2023-04-11 |
Family
ID=77223271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110477846.4A Active CN113248572B (en) | 2021-04-30 | 2021-04-30 | Anti-multidrug-resistant bacteria cyclopeptide and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113248572B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003302237A8 (en) * | 2002-12-06 | 2004-06-30 | Adaptive Therapeutics Inc | Novel cyclic peptides comprising alpha-, beta- and gamma- amino acids |
CN101622271A (en) * | 2007-01-16 | 2010-01-06 | 加利福尼亚大学董事会 | Novel antimicrobial peptides |
CN107141338A (en) * | 2017-05-02 | 2017-09-08 | 东北农业大学 | A kind of antibacterial peptide RW P and preparation method thereof and application |
CN110066320A (en) * | 2019-05-06 | 2019-07-30 | 重庆理工大学 | Anti- multi-drug resistant bacteria cyclic peptide and its preparation method and application |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0005703D0 (en) * | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
CA2597191C (en) * | 2005-02-09 | 2014-04-01 | Helix Biomedix Inc. | Antimicrobial hexapeptides |
CN102391362B (en) * | 2011-12-13 | 2014-05-07 | 重庆理工大学 | Group of animal-derived cationic antibacterial peptides and its application |
CN102432672A (en) * | 2011-12-13 | 2012-05-02 | 重庆理工大学 | Novel synthesis antibacterial peptides and application thereof |
CN104356202A (en) * | 2014-11-06 | 2015-02-18 | 西南大学 | Cationic antibacterial peptide as well as preparation method and application thereof |
CN106916205B (en) * | 2017-03-31 | 2020-10-13 | 重庆理工大学 | Antibacterial hexapeptide and derivatives and application thereof |
WO2019085926A1 (en) * | 2017-10-31 | 2019-05-09 | 上海医药工业研究院 | Polymyxin analogue and preparation method therefor |
WO2019136139A2 (en) * | 2018-01-03 | 2019-07-11 | Board Of Regents, The University Of Texas System | Antimicrobial peptides and use thereof |
GB2582571B (en) * | 2019-03-25 | 2024-02-28 | Syntherix Ltd | Peptides and use thereof |
EP4021476A4 (en) * | 2019-08-29 | 2023-10-11 | AJK Biopharmaceutical, LLC | Synthetic antimicrobial peptides |
CN112521454A (en) * | 2020-11-25 | 2021-03-19 | 微科健康科技(广州)有限公司 | Targeting antibacterial peptide for salmonella and preparation method thereof |
-
2021
- 2021-04-30 CN CN202110477846.4A patent/CN113248572B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003302237A8 (en) * | 2002-12-06 | 2004-06-30 | Adaptive Therapeutics Inc | Novel cyclic peptides comprising alpha-, beta- and gamma- amino acids |
CN101622271A (en) * | 2007-01-16 | 2010-01-06 | 加利福尼亚大学董事会 | Novel antimicrobial peptides |
CN107141338A (en) * | 2017-05-02 | 2017-09-08 | 东北农业大学 | A kind of antibacterial peptide RW P and preparation method thereof and application |
CN110066320A (en) * | 2019-05-06 | 2019-07-30 | 重庆理工大学 | Anti- multi-drug resistant bacteria cyclic peptide and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN113248572A (en) | 2021-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109232719B (en) | PH-responsive antibacterial peptide and preparation method and application thereof | |
CN110283253B (en) | Pig-derived hybrid antibacterial peptide MDP-2 and preparation method and application thereof | |
CN114031671B (en) | Antibacterial peptide targeting fungi and preparation method and application thereof | |
CN116874614B (en) | Antibacterial polypeptide APH171 with high activity and low cracking effect, and preparation method and application thereof | |
CN107344958B (en) | Antibacterial pentapeptide derivative and application thereof | |
CN113292636A (en) | Antibacterial hexapeptide and application thereof | |
CN106749559B (en) | Antibacterial peptide based on cell-penetrating peptide Tat (49-57) and synthesis method thereof | |
CN115947788A (en) | Tryptophan and leucine cross-chain interaction beta-hairpin antibacterial peptide WLF, and preparation method and application thereof | |
CN117586352A (en) | Antibacterial polypeptide APH220 based on salivary glands of Hirudinaria manillensis and application thereof | |
CN110066320B (en) | Cyclic peptide resisting multiple drug-resistant bacteria and preparation method and application thereof | |
CN106916205B (en) | Antibacterial hexapeptide and derivatives and application thereof | |
CN112625106B (en) | Antibacterial polypeptide compound, synthesis method and application thereof | |
CN110283245B (en) | Pig marrow derived PMAP-23 derived antibacterial peptide, preparation method and application | |
CN112625092A (en) | Antibacterial polypeptide compound based on polybia-MPI and synthesis and application thereof | |
CN116813712B (en) | Antibacterial peptide W33 with alpha-helical structure and rich in Trp, and preparation method and application thereof | |
CN113248572B (en) | Anti-multidrug-resistant bacteria cyclopeptide and application thereof | |
CN113214355A (en) | Special antifungal antibacterial peptide GL4W as well as preparation method and application thereof | |
CN111253474B (en) | Antibacterial peptide RG-27 and application thereof | |
CN114805495B (en) | Enzymolysis-resistant branched antibacterial peptide Pal-CRKP, and preparation method and application thereof | |
CN113185576B (en) | Beta-hairpin type low-toxicity broad-spectrum antibacterial peptide with RRRF corner and application thereof | |
CN113880933B (en) | Antibacterial peptide SsNKL27 and application thereof | |
CN115772207A (en) | Fmoc group induction-based self-assembly antibacterial peptide W7ff, preparation method thereof and application of self-assembly structure thereof | |
CN110272501B (en) | Pig source hybrid defense peptide PL-5 and preparation method and application thereof | |
CN111100190B (en) | Wasp venom peptide reverse sequence analogue WVD-II and preparation method and application thereof | |
CN108610428B (en) | Antibacterial fusion peptide and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |